Clinical Trials
2 trialsNCT05358691 2025-04-16
A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants
Rutgers, The State University of New Jersey
Phase 1 Withdrawn
NCT05383001 2022-09-27
Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)
AIO-Studien-gGmbH
Phase 2 Withdrawn